Wetland management to reduce Baltic Sea eutrophication.

Seven regions with coastal eutrophication problems in the Baltic Sea, including the Kattegat, constitute the BERNET project (Baltic Eutrophication Regional Network). To counteract eutrophication and associated severe biological conditions the countries around this large brackish water body must all cooperate. The regions are characterized by large differences in land use, e.g. agricultural intensity, and losses of retention capacity in the catchments due to wetland reclamation. Initially it has been necessary to identify nutrient sources--especially nitrogen--and technical, economical and even administrative obstacles to initiate eutrophication management measures. Nitrogen retention in different types of wetlands in the Baltic Sea Region has been analysed. The wetlands generally have a positive effect on reduced nitrogen transport to aquatic environments and it is generally accepted that measures leading to decreased losses of nutrients to the aquatic environment must be combined with measures leading to increased retention of nutrients in catchments. Data analysed in the BERNET project show that the potential for such a measure is large. Therefore, conservation and restoration initiatives for wetlands is an essential part of the work in the BERNET project. Wetlands have been drained or totally eliminated due to intensive agriculture in some regions while large scale rehabilitation of wetlands occurs in regions with less intensive agriculture. Based on land use data from the seven regions, the working group for wetland management within the BERNET project has identified the possible use of wetlands as building blocks as a contribution to the management of the Baltic Sea eutrophication. Several recommendations are presented on the wise use of existing and constructed wetlands for water quality management in relation to non-point nutrient pollution.

Developing and advancing dry powder inhalation towards enhanced therapeutics.

Enhanced therapeutics are drug products derived from existing generic drugs that provide additional benefits to the patients and the healthcare system. Enhanced therapeutics are considered to be an important and relatively low risk source of innovation. Pulmonary drug delivery is the major delivery route to treat chronic respiratory diseases and has been proven as a potential delivery route for complex drugs that cannot be delivered orally. Development of dry powder inhalation systems targets the delivery of fine drug particles to the deep lung surface by a combination of drug formulation, primary packaging and a device, whereby each contributes to the overall performance. Various methodologies for the non-clinical and clinical performance testing of orally inhaled products have been proposed and applied with variable success. Regulatory pathways have been developed and applied since. Considerable efforts have been made during the past decade to understand and optimize pulmonary drug delivery including their efficient commercial manufacturing. Pulmonary drug delivery remains an area of future innovation in the effective treatment of pulmonary diseases as well as the systemic delivery of systemically active complex drugs.

Arteriolar vasodilatation in frog skeletal muscle in vivo: modification of second messenger systems.

This study was concerned with the role of cyclic nucleotides in the post-junctional vasodilatation mechanism. Interventions with second messenger systems involving cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP), allowed the role of these nucleotides in vascular smooth muscle to be evaluated in the autoperfused, transparent frog muscle, m. cutaneous pectoris. The microcirculation was observed by intravital microscopy, and arteriolar diameters were continuously recorded. Pre- and post-junctional effects were distinguished by comparing results in control frogs with those obtained in frogs that had been chemically sympathectomized with either 6-hydroxydopamine or tetrodotoxin. Arterioles that were pre-contracted with adrenaline dilated in response to topical application of forskolin or sodium nitroprusside, which are direct activators of intracellular adenylate cyclase and guanylate cyclase, respectively. Arterioles were also dilated by 3-isobutyl-1-methylxanthine (IBMX), which is a non-selective inhibitor of cyclic AMP- and cyclic GMP-phosphodiesterase, and by rolipram, which is a selective inhibitor of the calcium-independent cyclic AMP-phosphodiesterase. Dibutyryl-cyclic AMP and dibutyryl-cyclic GMP also caused vasodilatation. These results indicate that in vascular smooth muscle, intracellular mechanisms involving cyclic nucleotides (cyclic AMP and cyclic GMP) are important in vasodilatation. They may act in conjunction with pre-junctional inhibitory mechanisms on sympathetic nerves.

Presynaptic inhibition of sympathetic fibers participating in vasodilatation in response to K+-induced contraction of frog skeletal muscle.

Experiments were performed on an autoperfused transparent frog muscle (m. cutaneus pectoris) with the purpose of elucidating possible mechanisms of functional hyperaemia. The diameter of a primary arteriole was followed before and after a K+-induced contracture lasting 20 s. The vasodilatation following this period of activity was expressed as the diameter change relative to the maximal possible diameter increase. The results emphasize adenosine as an important substance participating in vasodilatation in active skeletal muscle, its effect possibly being presynaptic (prejunctional) inhibition of sympathetic vasoconstrictor fibers to arteriolar smooth muscle (sympathetic uncoupling), in addition to the well-known direct effect (relaxation) on vascular smooth muscle cells. The presence of a strong resting sympathetic tone was demonstrated by local application of phentolamine (7.1 X 10(-5) M) that led to a large diameter increase. The purinoceptor blocking agent, 8-phenyltheophylline (8-PTP) invariably attenuated post-contraction vasodilatation, the adenosine transport inhibitor dipyridamole (10(-5) M) increased the hyperaemia response. Lack of sympathetic arteriolar tone during hyperaemia was demonstrated by the absence of a dilatory effect of phentolamine applied in the post-contraction period. Conversely, blockage of purinoceptors by 8-PTP during and after the contracture allowed sympathetic discharge to continue as verified by application of phentolamine, now leading to further vasodilatation. We suggest that presynaptic inhibition of sympathetic nerve endings by adenosine participates in vasodilatation in frog skeletal muscle.

Blood-brain transfer of glucose and glucose analogs in newborn rats.

Little is known of the selectivity of the blood-brain barrier at birth. Hexoses are transported through the barrier by a facilitating mechanism. To study the capacity of this mechanism to distinguish between analogs of D-glucose, we compared the transport of fluorodeoxyglucose, deoxyglucose, glucose, methylglucose, mannose, galactose, mannitol, and iodoantipyrine across the cerebral capillary endothelium in newborn Wistar rats. Cerebral blood flow, glucose consumption, and the blood-brain permeabilities of the hexoses were 25-50% of the adult values but the ratios between the permeabilities of the individual hexoses were similar to the ratios observed in adult rats. The mannitol clearance into brain was considerably higher than in adult rats (about 10-fold), indicating a higher endothelial permeability to small polar nonelectrolytes. The brain water content was higher in newborn than in adult rats and was associated with a higher steady-state distribution of labeled methylglucose between brain and blood. Hexose concentrations were determined relative to whole blood because the apparent erythrocyte membrane permeability to glucose was as high as in humans and thus considerably higher than in adult rats. The half-saturation concentration of glucose transport across the blood-brain barrier was considerably higher than in adult rats, about three-fold, suggesting that net blood-brain glucose transfer is less sensitive to blood glucose fluctuation in newborn than in adult rats.

Presynaptic modulation of sympathetic nerve transmission--an element in vasomotor control.

We have earlier presented evidence that adenosine may create vasodilation via presynaptic inhibition of sympathetic nerve fibers to muscle arterioles. In the present study the effect of selective adenosine antagonists on arteriolar diameter was investigated, using an autoperfused frog muscle (m. cutaneus pectoris). During application of the antagonists arteriolar diameter reductions were observed in the transparent, transilluminated muscle. The sulfonylated xanthine derivatives 8-(p-sulfo)phenyltheophylline (8-PS phi T), 8-(m-sulfo)phenyltheophylline (8-MS phi T) and 1,3-dipropyl-8-p-sulfonphenylxanthine (DPSPX) are all considered to be selective competitive adenosine antagonists without unspecific intracellular effects. Topical application of each of these compouns on resting muscle resulted in a dose-dependent arteriolar contraction. The constriction was immediately reversed by addition of the adrenergic alpha-receptor blocker phentolamine (7.1 x 10(-5) M), indicating that the arteriolar contraction was due to activation of postjunctional alpha-receptors present in vascular smooth muscle. Also, the A1-selective adenosine agonist (-)-N6-(R-phenylisopropyl)-adenosine (R-PIA) eliminated the arteriolar constriction. These effects suggest, that the xanthine derivatives release the sympathetic nerve terminals from inhibition by endogenous adenosine. When nerve fibers were blocked by tetrodotoxin (TTX), 3 x 10(-6)M or when the frogs had been chemically sympathectomized with 6-hydroxydopamine (6-OHDA), no significant arteriolar contraction was observed during adenosine antagonist administration, complying with the view that in resting muscle endogenous adenosine acts presynaptically to inhibit sympathetic nerve terminals. These results suggest that presynaptic adenosine effects are not only involved in regulation of frog skeletal muscle blood flow in response to activity, but also play a role in the control of arteriolar tone in resting muscle.

Flash photolysis studies of relaxation and cross-bridge detachment: higher sensitivity of tonic than phasic smooth muscle to MgADP.

The effects of MgADP and inorganic phosphate (Pi) on cross-bridge detachment were determined in tonic (rabbit femoral artery) and phasic (rabbit bladder and guinea pig portal vein) smooth muscles permeabilized with staphylococcal alpha-toxin. Relaxation from rigor was induced by photolysis of ATP (1.2-1.5 mM) from caged ATP. The initial one second of relaxation from rigor was resolved into two exponential components: a rapid component with normalized amplitudes, Af, of 8, 15 and 26% and rate constants, kf (in s-1) of 26, 36 and 30 in rabbit femoral artery, guinea pig portal vein, and rabbit bladder; the respective rate constants of the second, slower component, ks, were 0.07, 0.2 and 0.1. Removal of residual endogenous ADP with apyrase treatment increased the amplitude Af and accelerated ks; addition of MgADP reduced Af. The combination of these effects (increases in Af and ks) decreased the t1/2 of relaxation from control values by factors of 2.6 (femoral artery), 6.7 (portal vein) and 10 (bladder). Pi (30 mM) further increased the amplitudes Af. The affinity of MgADP for myosin cross-bridges, estimated as the reduction of the relative amplitude of the rapid component, Af, was significantly higher in tonic than in phasic smooth muscle: the KD of MgADP was 1.1 +/- 0.3 microM in rabbit femoral artery and 4.9 +/- 1.0 microM in rabbit bladder. The higher affinity of tonic smooth muscle myosin for MgADP correlated with its relatively high LC17b isoform content (58 +/- 4.2%) in contrast to the lower affinity of the phasic, bladder detrusor smooth muscle that contained only the LC17a isoform.(ABSTRACT TRUNCATED AT 250 WORDS)

Phosphorylation-independent interaction between 14-3-3 protein and the plant plasma membrane H+-ATPase.

14-3-3 proteins interact with a novel phosphothreonine motif (Y(946)pTV) at the extreme C-terminal end of the plant plasma membrane H(+)-ATPase molecule. Phosphorylation-independent binding of 14-3-3 protein to the YTV motif can be induced by the fungal phytotoxin fusicoccin. The molecular basis for the phosphorylation-independent interaction between 14-3-3 and H(+)-ATPase in the presence of fusicoccin has been investigated in more detail. Fusicoccin binds to a heteromeric receptor that involves both 14-3-3 protein and H(+)-ATPase. Binding of fusicoccin is dependent upon the YTV motif in the H(+)-ATPase and, in addition, requires residues further upstream of this motif. Apparently, 14-3-3 proteins interact with the unusual epitope in H(+)-ATPase via its conserved amphipathic groove. This implies that very diverse epitopes bind to a common structure in the 14-3-3 protein.

Arachidonic acid inhibits myosin light chain phosphatase and sensitizes smooth muscle to calcium.

Arachidonic acid (AA) increased, at constant Ca2+, the levels of force and 20-kDa myosin light chain (MLC20) phosphorylation in permeabilized smooth muscle, and slowed relaxation and MLC20 dephosphorylation. The Ca(2+)-sensitizing effect of AA was not inhibited by inhibitors of AA metabolism (indomethacin, nordihydroguaiaretic acid, or propyl gallate), of protein kinase C (pseudopeptide) or by guanosine-5'-O-(beta-thiodiphosphate) and was abolished by oxidation of AA in air. A non-metabolizable AA analog, 5,8,11,14-eicosatetraynoic acid) also had Ca(2+)-sensitizing effects. Extensive treatment with saponin abolished the Ca(2+)-sensitizing effects of phorbol 12,13-dibutyrate and guanosine-5'-O-(gamma-thiotriphosphate), but not that of AA. A purified, oligomeric MLC20 phosphatase isolated from gizzard smooth muscle was dissociated into subunits by AA, and its activity was inhibited toward heavy meromyosin but not phosphorylase. We conclude that AA may act as a messenger-promoting protein phosphorylation through direct inhibition of the form of protein phosphatase(s) that dephosphorylate MLC20 in vivo.

The 14-3-3 proteins associate with the plant plasma membrane H(+)-ATPase to generate a fusicoccin binding complex and a fusicoccin responsive system.

The plasma membrane H(+)-ATPase in higher plants has been implicated in nutrient uptake, phloem loading, elongation growth and establishment of turgor. Although a C-terminal regulatory domain has been identified, little is known about the physiological factors involved in controlling the activity of the enzyme. To identify components which play a role in the regulation of the plant H(+)-ATPase, a fusicoccin responsive yeast expressing Arabidopsis plasma membrane H(+)-ATPase AHA2 was employed. By testing the fusicoccin binding activity of yeast membranes, the C-terminal regulatory domain of AHA2 was found to be part of a functional fusicoccin receptor, a component of which was the 14-3-3 protein. ATP hydrolytic activity of AHA2 expressed in yeast internal membranes was activated by all tested isoforms of the 14-3-3 protein of yeast and Arabidopsis, but only in the presence of fusicoccin, and activation was prevented by a phosphoserine peptide representing a known 14-3-3 protein binding motif in Raf-1. The results demonstrate that the 14-3-3 protein is an activator molecule of the H(+)-ATPase and provides the first evidence of a protein involved in activation of plant plasma membrane H(+)-ATPase.

Binding of 14-3-3 protein to the plasma membrane H(+)-ATPase AHA2 involves the three C-terminal residues Tyr(946)-Thr-Val and requires phosphorylation of Thr(947).

14-3-3 proteins play a regulatory role in a diverse array of cellular functions such as apoptosis, regulation of the cell cycle, and regulation of gene transcription. The phytotoxin fusicoccin specifically induces association of virtually any 14-3-3 protein to plant plasma membrane H(+)-ATPase. The 14-3-3 binding site in the Arabidopsis plasma membrane H(+)-ATPase AHA2 was localized to the three C-terminal residues of the enzyme (Tyr(946)-Thr-Val). Binding of 14-3-3 protein to this target was induced by phosphorylation of Thr(947) (K(D) = 88 nM) and was in practice irreversible in the presence of fusicoccin (K(D) = 7 nM). Mass spectrometry analysis demonstrated that AHA2 expressed in yeast was phosphorylated at Thr(947). We conclude that the extreme end of AHA2 contains an unusual high-affinity binding site for 14-3-3 protein.

The 14-3-3 protein interacts directly with the C-terminal region of the plant plasma membrane H(+)-ATPase.

Accumulating evidence suggests that 14-3-3 proteins are involved in the regulation of plant plasma membrane H(+)-ATPase activity. However, it is not known whether the 14-3-3 protein interacts directly or indirectly with the H(+)-ATPase. In this study, detergent-solubilized plasma membrane H(+)-ATPase isolated from fusicoccin-treated maize shoots was copurified with the 14-3-3 protein (as determined by protein gel blotting), and the H(+)-ATPase was recovered in an activated state. In the absence of fusicoccin treatment, H(+)-ATPase and the 14-3-3 protein were well separated, and the H(+)-ATPase was recovered in a nonactivated form. Trypsin treatment removed the 10-kD C-terminal region from the H(+)-ATPase as well as the 14-3-3 protein. Using the yeast two-hybrid system, we could show a direct interaction between Arabidopsis 14-3-3 GF14-phi and the last 98 C-terminal amino acids of the Arabidopsis AHA2 plasma membrane H(+)-ATPase. We propose that the 14-3-3 protein is a natural ligand of the plasma membrane H(+)-ATPase, regulating proton pumping by displacing the C-terminal autoinhibitory domain of the H(+)-ATPase.